Todos Medical Ltd. operates as an in vitro diagnostics company, concentrating on the creation and commercialization of blood tests for the early detection of cancer and Alzheimer's disease, primarily serving the United States market. The company's innovative approaches to cancer diagnostics include the Total Biochemical Infrared Analysis (TBIA), a proprietary screening technology that uses peripheral blood spectroscopy to investigate cancer's effects on the immune system. Another key offering is the Lymphocyte Proliferation Test (LPT), a diagnostic blood assay designed to assess how peripheral blood lymphocytes and monocytes react to exogenous mitogenic stimulation, which induces cell cycle entry. Their cancer product lineup includes TM-B1 and TM-B2 for breast cancer screening, alongside the TMC blood test for diagnosing colon cancer. Beyond oncology, Todos Medical is also actively developing blood-based tests for identifying neurodegenerative conditions, notably Alzheimer's disease. In addition to its diagnostic portfolio, the company markets Tollovid, a dietary supplement acting as a 3CL protease inhibitor, formulated to bolster a healthy immune response against common coronaviruses. Furthermore, Tollovir, an antiviral treatment for Covid-19, is currently progressing through Phase 2 clinical trials. Todos Medical Ltd. engages in strategic alliances, including a collaboration with Integrated Health LLC, and has various agreements in place for developing SARS-nCoV-2 screening tests and distributing specific COVID-19 test kits. The company was incorporated in 2010 and is headquartered in Tel Aviv, Israel.